Table 2.
Representative FDA-approved drugs or clinical trials of nanomedicine against HMs
| Product name | Carrier | Drug | Status | Outcome or State | Identifier |
|---|---|---|---|---|---|
| Leukemia | |||||
| Marqibo kit | Liposome | Vincristine | Approved | ||
| Vyxeos | Liposome | Ara-C, DOX | Approved | ||
| Oncaspar | PEG | Pegaspargase | Approved | ||
| MB-106 | Liposome | Annamycin | Phase 1 | 80% Overall Response Rate in Final Cohort of Phase 1 | NCT05319587 |
| Lymphoma | |||||
| 2022–0453 | Liposome | MTX | Phase 2 | P2, Second Affiliated Hospital, School of Medicine, Zhejiang University N = 45, Recruiting | NCT05495100 |
| MM | |||||
| MCC-17814 | Liposome | DOX | Completed | P2, H. Lee Moffitt Cancer Center and Research Institute | NCT02186834 |
| Liposome | MTX | Phase 1 | P1, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. N = 60, Recruiting | NCT05052970 | |
| MDS | |||||
| TLK199 HCl | Liposome | Ezatiostat, HCL | Phase 2 | P2, Telik, N = 65, Completed | NCT00035867 |
| NCI-2018–01812 | Liposome | Ara-C, DOX | Phase 2 | P2, M.D. Anderson Cancer Center N = 50, Recruiting | NCT03672539 |
| AEB1102 | PEG | Human arginase I | Phase 2 | P2, Aeglea Biotherapeutics, N = 29, Completed | NCT02732184 |
MTX mitoxantrone, HCL hydrochloride